{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-026259","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.012168+00:00","generated_at":"2026-05-15T05:09:12.185201+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory","bullets":["FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.","Selective CBP degrader FHT-171 showed strong anti-tumor activity and favorable tolerability in heavily pretreated ER+ breast cancer PDX models.","Selective EP300 degrader outperformed clinical benchmark inobrodib in multiple myeloma models, including pomalidomide-resistant xenografts.","Cereblon-based selective ARID1B degraders achieved robust degradation with potential for oral bioavailability."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-026259","json":"https://secwatch.observer/filing/0001628280-26-026259.json","markdown":"https://secwatch.observer/filing/0001628280-26-026259.md","text":"https://secwatch.observer/filing/0001628280-26-026259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026026259/0001628280-26-026259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026026259/fhtx-20260421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:09:12.185201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}